arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Beam Therapeutics Inc.

BEAM Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$30.17
▲ +1.7% Today
as of Sep 4, 16:46 ET
Last 30 days +12.82% Jul 28 → Sep 04
$25.08 $26.68 $28.28 $29.87 $31.47 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$28.91
High
$29.97
Low
$28.91
Volume
$1M
Avg Vol
$2M
Mkt Cap
$2.7B
P/E (TTM)
—
Beta
—
52w High
$38.26
52w Low
$19.36
Div Yield
—
Shares Out
$103M

Recent Press Releases & News last 60 days · 16 items

Sep 1 · 11:00 PR GlobeNewswire
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
Aug 31 · 11:00 PR GlobeNewswire
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
Aug 26 · 06:20 Simply Wall St.
Beam Therapeutics (BEAM) Stock May Look Stretched As Sales Expectations Climb
▸ Show all 16 press releases & news Free account →

Overview

52-week range
$19
$38
57% of range
Avg surprise (last 3)
-4.2%
Avg reaction (last 2)
-11.0%
0% positive
Latest IV / EM
95%
EM ±14.9% · $30 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.33$-0.75$-0.17$0.42$1.00 Actual $-1.33Actual $-1.08Actual $-1.22Actual $-1.21Actual $-1.11Actual $-1.17Actual $-1.24Est $-1.11Actual $1.00Est $-1.04Actual $-1.10Actual $-0.91Est $-0.87Actual $-1.18 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-123M$-84M$-45M$-6M$33M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.18 — — — — financials
Thu May 7, 2026Mar/2026 $-0.91 $-0.87 -4.6% +26.6% -2.7% earnings
Tue Sep 30, 2025Sep 2025 $-1.10 — — — — financials
Tue Aug 5, 2025Jun/2025 $1.00 $-1.04 +3.9% — — earnings
Tue May 6, 2025Mar/2025 $-1.24 $-1.11 -11.7% — -19.3% earnings
Mon Sep 30, 2024Sep 2024 $-1.17 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.11 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.21 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.22 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.08 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.33 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$490,000$32M—$10M$8M$7M—$14M
Cost of revenue————————
Gross profit————————
Operating income$-127M$-107M—$-127M$-120M$-119M—$-107M
Net income$-123M$-94M—$-113M$-102M$-108M—$-97M
EPS (diluted)$-1.18$-0.91—$-1.10$-1.00$-1.23—$-1.17

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$220M$288M$295M$268M$282M$528M$282M$230M
Inventory————————
Total current assets$1.18B$1.27B$1.27B$1.10B$1.18B$1.25B$878M$946M
Total assets$1.39B$1.48B$1.48B$1.31B$1.39B$1.47B$1.10B$1.17B
Long-term debt$100M$100M——————
Total liabilities$319M$316M$243M$345M$344M$344M$370M$380M
Total equity$1.07B$1.16B$1.24B$966M$1.05B$1.13B$734M$791M

Implied volatility — last 90 days

29%64%99%135%170% Jun 07 — IV 117% · EM ±16.2%Jun 08 — IV 153% · EM ±20.2%Jun 09 — IV 145% · EM ±18.2%Jun 10 — IV 97% · EM ±11.4%Jun 11 — IV 78% · EM ±8.7%Jun 12 — IV 170% · EM ±17.4%Jun 15 — IV 83% · EM ±6.0%Jun 17 — IV 80% · EM ±3.3%Jun 19 — IV 74% · EM ±16.4%Jun 22 — IV 72% · EM ±15.0%Jun 23 — IV 87% · EM ±17.8%Jun 24 — IV 84% · EM ±16.9%Jun 25 — IV 81% · EM ±15.9%Jun 26 — IV 80% · EM ±15.3%Jun 29 — IV 87% · EM ±15.4%Jun 30 — IV 86% · EM ±14.7%Jul 01 — IV 92% · EM ±15.4%Jul 02 — IV 93% · EM ±15.1%Jul 03 — IV 97% · EM ±15.1%Jul 06 — IV 118% · EM ±16.3%Jul 07 — IV 92% · EM ±12.2%Jul 08 — IV 68% · EM ±8.5%Jul 09 — IV 79% · EM ±9.4%Jul 10 — IV 148% · EM ±16.3%Jul 13 — IV 67% · EM ±5.6%Jul 14 — IV 29% · EM ±2.1%Jul 15 — IV 56% · EM ±3.3%Jul 16 — IV 88% · EM ±3.7%Jul 20 — IV 95% · EM ±22.3%Jul 21 — IV 75% · EM ±17.5%Jul 22 — IV 83% · EM ±19.0%Jul 23 — IV 63% · EM ±14.2%Jul 24 — IV 67% · EM ±14.7%Jul 27 — IV 87% · EM ±18.1%Jul 28 — IV 80% · EM ±16.5%Jul 29 — IV 89% · EM ±17.8%Jul 30 — IV 89% · EM ±17.4%Jul 31 — IV 85% · EM ±16.3%Aug 03 — IV 75% · EM ±13.3%Aug 04 — IV 85% · EM ±14.6%Aug 05 — IV 92% · EM ±15.4%Aug 06 — IV 70% · EM ±11.3%Aug 07 — IV 90% · EM ±14.1%Aug 10 — IV 112% · EM ±15.6%Aug 11 — IV 82% · EM ±10.9%Aug 12 — IV 122% · EM ±15.3%Aug 13 — IV 68% · EM ±8.0%Aug 14 — IV 77% · EM ±8.5%Aug 17 — IV 74% · EM ±6.2%Aug 18 — IV 93% · EM ±6.7%Aug 19 — IV 82% · EM ±4.8%Aug 20 — IV 91% · EM ±3.8%Aug 24 — IV 72% · EM ±15.1%Aug 25 — IV 105% · EM ±21.5%Aug 26 — IV 87% · EM ±17.5%Aug 27 — IV 94% · EM ±18.5%Aug 28 — IV 85% · EM ±16.2%Aug 31 — IV 119% · EM ±21.1%Sep 01 — IV 83% · EM ±14.3%Sep 02 — IV 82% · EM ±13.7%Sep 03 — IV 93% · EM ±15.0%Sep 04 — IV 95% · EM ±14.9%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in